Affinity Asset Advisors »

Nextcure shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Nextcure (NXTC) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Nextcure

Tip: Access up to 7 years of quarterly data

All positions including Nextcure held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Nextcure by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2024-03-31 $3.0M 1.4M 2.23

More positions owned by Affinity Asset Advisors

Spdr Ser Tr S&p Biotech Put Option (XBI)
Teva Pharmaceutical Inds Sponsored Ads Call Option (TEVA)
Moderna Put Option (MRNA)
Apogee Therapeutics (APGE)
Xenon Pharmaceuticals (XENE)
Madrigal Pharmaceuticals (MDGL)
Crinetics Pharmaceuticals In (CRNX)
Autolus Therapeutics Spon Ads (AUTL)
Celldex Therapeutics Com New (CLDX)
Arcellx Common Stock (ACLX)
Vera Therapeutics Cl A (VERA)
Inozyme Pharma (INZY)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Kura Oncology (KURA)
Spyre Therapeutics Com New (SYRE)

View all positions for Affinity Asset Advisors

Top funds holding Nextcure

Sofinnova Ventures
Logos Global Management
Affinity Asset Advisors
OrbiMed Advisors
Millennium Management
Vanguard Group
BlackRock
Cable Car Capital
Long Focus Capital Management
Acadian Asset Management
Assenagon Asset Management
Morgan Stanley
Renaissance Technologies
Schonfeld Strategic Advisors
Federated Investors

View all funds holding Nextcure